Objective: To investigate possible underlying mechanisms for alterations in lamotrigine (LTG) kinetics by gestation and use of contraceptives. Methods: Plasma concentrations of LTG and its main metabolite lamotrigine-2-Nglucuronide (2-N-GLUC) were measured in 31 women on LTG taking combined oral contraceptives (COC), in 12 with contraceptive intrauterine devices containing levonorgestrel (CIUD), and in 20 on LTG without hormonal contraception (controls). We also measured the levels of LTG and 2-N-GLUC in plasma and urine in eight women during pregnancy, and up to three months postpartum. LTG levels in plasma were measured by high-performance liquid chromatography method (HPLC) and N-2-GLUC in urine and plasma and LTG in urine by liquid chromatography-mass spectrometry (LC/MS). Results: There were no significant differences in LTG dose/concentration (D/C), or N-2-GLUC/LTG ratios between women with CIUD and controls. In contrast, compared to controls, the LTG D/C ratio was 56% higher in women taking COC (mean AE SD, 83 AE 47 versus 53.0 AE 24.2; p < 0.01) and N-2-GLUC/LTG ratio 82% higher in women taking COC (mean 0.477 AE 0.212 SD versus 0.262 AE 0.127; p < 0.0003.
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The 2-GLUC/LTG ratios were 154% higher in plasma and 122% higher in urine in late pregnancy compared with baseline 3 months postpartum. Conclusions: Our data indicate that the alterations in LTG kinetics in pregnancy as well as those induced by COC are mainly explained by enzymatic induction of the N-2-glucuronide pathway. In addition we found no evidence for an interaction between LTG and CIUD. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Introduction
Lamotrigine (LTG) has become the most widely used among newer antiepileptic drugs (AED) in women with epilepsy that are of reproductive age.
LTG is metabolized via glucuronidation by uridindiphosphate glucuronosyltransferase (UGT), and is mainly formed to an inactive 2-N-glucuronide (2-N-GLUC) by isoenzyme UGT1A4. 1 Three additional minor metabolites, lamotrigine-2-N-methyl, lamotrigine-2-N-oxide, and lamotrigine-5-N-glucuronide have been proposed, but there is no conclusive evidence of their presence in humans. 2 LTG plasma concentrations are substantially lower during comedication with combined oral contraceptives (COC), compared with when LTG is taken alone. [3] [4] [5] [6] Several studies have also revealed marked alterations in LTG kinetics during pregnancy with a significant increase in the apparent clearance. [7] [8] [9] [10] [11] [12] Induction of glucuronidation by hormonal factors has been proposed as the mechanism, and two recent reports provide some support for this hypothesis based on measurements of LTG metabolites in plasma during pregnancy and in urine in conjunction with use of COC. 6, 13 The aim of this study was to advance our understanding of the role of induction of the 2-N-GLUC pathway for the effects of pregnancy and hormonal contraception on LTG disposition by extending our previous series of pregnant women as well as study women on different types of contraception and by measuring metabolites in plasma as well as urine.
Patients and methods

Contraception
Women between 15 and 45 years of age, who were on LTG in monotherapy or in combination therapy with drugs not known to affect LTG kinetics, were asked to participate. Blood samples were collected immediately before the morning dose (trough concentration) at steady-state and concentrations of LTG and its main metabolite 2-N-GLUC were measured in plasma. Thirty-one women were taking LTG in combination with COC, 12 women were using intrauterine contraception containing levonorgestrel (CIUD), and 20 women on LTG monotherapy but without hormonal contraception served as controls (the same controls have been used in a previous publication 13 ). The LTG dose/plasma concentration (C/D) and 2-GLUC/LTG ratios were determined and compared between the three groups.
Pregnancy
Eight women on LTG in monotherapy (or with comedication known not to interact with LTG) were included. Their characteristics are summarised in Table 1 . Blood samples for determination of LTG and 2-N-GLUC were obtained before the morning dose once each trimester and at baseline up to three months after delivery. In addition, 24 h urine collections were obtained on the same occasions for determination of LTG and 2-N-GLUC. Ratios of 2-GLUC/LTG were determined in plasma and urine and compared between the different stages of pregnancy and postpartum.
Drug analytical method
LTG concentrations in plasma were determined by an established routine high-performance liquid chromatography method (HPLC).
14 Using this method, the range of quantification for LTG is 2-100 mmol/L with a coefficient of variation (CV) for LTG of less than 8%. The limit of detection is 0.2 mmol/L.
Plasma concentrations of 2-N-GLUC were measured by a newly developed method based on liquid 200 I. Öhman et al. chromatography-mass spectrometry (LC/MS). 2 The range of quantification is 0.2 to 50 mmol/L with a CV less than 16%. The limit of detection is 0.05 mmol/L. LTG and N-2-glucuronide in urine were analyzed by using a modification of the LC/MS method developed for analysis of LTG and N-2-GLUC in plasma. 2 The measuring range of LTG and N-2-glucuronide in urine was 3-500 mmol/L. The coefficient of variation on urine was <5% for LTG and <16% for N-2-glucuronide.
Statistical analysis
The statistical analysis was performed using a Statistic Software version 7.0 (StatSoft Scandinavia AB, Uppsala, Sweden). Statistical comparison was conducted using t-test; p-values <0.05 were considered significant.
The study was approved by the Local Ethics Committees and all women gave their informed consent.
Results
Contraception
The LTG dose was 279 AE 156 mg/day (mean AE SD) among women taking COC compared with 262 AE 148 mg/day in controls (NS). COC users had 56% higher D/C than control women (mean AE SD, 83 AE 47 L/day versus 53.0 AE 24.2 L/day; p < 0.01) (Fig. 1 ) and the N-2-GLUC/LTG ratio was 82% higher in women taking COC compared with controls (mean 0.477 AE 0.212 SD versus 0.262 AE 0.127; p < 0.0003) (Fig. 2 ). There were no statistically significant differences in D/C, or N-2-GLUC/LTG ratios between controls and women with CIUD ( Figs. 1 and 2 ).
Pregnancy
The mean 2-N-GLUC/LTG ratio in plasma was 154% higher in late pregnancy than three months postpartum (mean 1.02 AE 0.271 SD, versus 0.40 AE 0.06; p < 0.01) (Fig. 3 ) and 122% higher in urine (mean 46.6 AE 17.2 SD, versus 21.0 AE 5.35; p < 0.01) (Fig. 4) .
Discussion
The results of this study confirm earlier reports on the significant effect of COC on LTG disposition. [3] [4] [5] [6] We also demonstrate that intrauterine levonorgestrel contraceptives seem to have no effect on LTG kinetics, which is in line with a previous report suggesting that progesterone only oral contraceptives do not seem to interact with LTG. 15 Effects of pregnancy and contraception on lamotrigine disposition 201 Our data, showing a markedly increased 2-N-GLUC/LTG ratio in plasma in women taking COC, strongly suggest that this interaction is to a large extent explained by an induction of UGT1A4, the isoenzyme responsible for the metabolism of LTG to 2-N-GLUC. Our findings are further supported by a placebo-controlled trial where the 2-N-GLUC/LTG ratio in urine decreased by $30% (NS) when COC was replaced by placebo. 6 The present study furthermore suggests that similar mechanisms may explain the marked decline in LTG plasma concentrations during pregnancy. [7] [8] [9] [10] [11] [12] We found in late pregnancy a 154% increase in the 2-N-GLUC/LTG ratio in plasma and 122% in urine compared with three months post partum. The changes in 2-N-GLUC/LTG ratios seen in plasma over the course of the pregnancy are closely mirrored by similar changes in urine.
In conclusion, our data show that the alterations of the pharmacokinetics in LTG in pregnancy as well as those induced by COC are mainly caused by enzymatic induction of the N-2-glucuronide pathway and suggest that similar hormonal factors may be instrumental in both situations.
